NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

The third combo partner might be Astra Zeneca with Durvalumab. I think they are more desperate than Merck or BMY. I don't think Durvalumab has been approved for anything yet. They partnered with TPIV, sharing trial costs and each paying for their drugs.

In fact, Durvalumab might make more sense to try than Opdivo or Keytudra because it is Anti-PD-L1 rather than Anti-PD-1.

If I read correctly, PD-L1 is on the tumor while PD-1 is on the T-Cells. Flipper and others have speculated that injecting the BI into, or near the target tumor(s) might greatly reduce the dose required. That would be a big deal. But if so, shouldn't the BI be Anti-PD-L1 and not Anti-PD-1.

Anti-PD-1 would be better for mets, but Anti-PD-L1 would be better for the tumor if applying directly to the tumor allows a drop in dosage.

If the combo of PD-L1 and Direct proves powerful, then there should be a powerful immune response to go with it, since so many neo-antigens and any other antigens that are immunogenic will be brought into the bloom / upward cycle. Such a strong immune response might take care of any mets, so Anti-PD-1 might not be necessary.